The role of arginine vasopressin deficiency in the regulation of the kidney fibrosis

Abstract

It is known that arginine vasopressin (AVP) participate in the regulation of the immune responses, including the scarring. However, the effect of how AVP regulates this process is not clear. Here we describe the impact of AVP deficiency induced by neurointermediate pituitary lobectomy (NIL) or blocking the V1a‐V2 AVP receptors with conivaptan (CON) on the kidney fibrosis (KF), induced by unilateral ureteral ligature (UUL). Groups of 5 Wistar male rats were prepared: Control Intact (CI), UUL, NIL, NIL+UUL, UUL+NIL and UUL+CON. The NIL group was operated 6 weeks before sacrifice. In the NIL+UUL group NIL was performed 3 weeks before UUL and sacrificed 3 weeks after. In the UUL+CON (3mg/kg/day/SC/3 weeks before sacrifice) the UUL was done 6 weeks before sacrifice. KF was evaluated in histological slides stained with H‐E, Masson and Sirius red. Results showed that UUL induced hydronephrosis, severe kidney fibrosis and loss of histological architecture, whose severity was related to each experimental condition: In the UUL severe fibrosis occurred in the ilium, pelvis, periglomerular, intraglomerular, intraluminal tubules and interstitial kidney areas. In comparison with the CI, NIL group showed normal kidney histology, whereas that, in comparison with the UUL the NIL+UUL group developed significant less histological alterations and less kidney fibrosis. In the UUL+NIL group (NIL surgery performed 3 weeks after UUL and sacrificed 3 weeks later), although histological changes and fibrosis were apparent, these were significantly less severe as compared with the UUL group. In comparison with the NIL+UUL group, the UUL+CON animals developed less severe fibrosis and less histopathological changes. Conclusions. Results showed that kidney fibrosis may be controlled by AVP deficiency or blocking the V1a‐V2 AVP receptors (CON) indicating a major role of AVP on the fibrotic process. Results also suggests that conivaptan may be used for kidney fibrosis treatment.Support or Funding InformationUniversidad Autónoma de Aguascalientes PIFF14‐1 and CONACYT 221262. México